Abstract
Introduction– Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Methods ‐ Our institution averages 35 allogeneic BMT's per year. In the past year we have seen two women with reversible cortical blindness secondary to CSA toxicity. Results ‐ Age (years) (Case 1; Case 2): 32; 22. Day post‐BMT: 41; 50. Peak CSA level (ng/ml): 1159; 632. Both had a history of renal toxicity requiring adjustment of CSA dosage. MRI ‐ both with diffuse white matter changes. EEG‐both with moderate to severe generalized slowing. Visual evoked potentials were markedly prolonged in both. Auditory evoked potentials: minimally abnormal; normal. Somatosensory evoked potentials ‐ both normal. Prompt improvement occurred with discontinuation of CSA. Followup neurophysiologic evaluations were normal, however structural changes remained on MRI. Conclusion ‐ As neurophysiologic studies closely follow the clinical status they should be included in the evaluation and followup of CSA neurotoxicity.
Original language | English (US) |
---|---|
Pages (from-to) | 423-429 |
Number of pages | 7 |
Journal | Acta neurologica Scandinavica |
Volume | 92 |
Issue number | 5 |
DOIs | |
State | Published - Nov 1995 |
Keywords
- bone marrow transplantation
- cyclosporine neurotoxicity
- neurophysiologic evaluation
ASJC Scopus subject areas
- Neurology
- Clinical Neurology